Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Clinical trial NCT05340413 · COMPLETED

Trial details

NCT number: NCT05340413
Sponsor: SOLTI Breast Cancer Research Group
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-negative Breast Cancer Metastatic Breast Cancer Triple Negative Breast Cancer

Start date: 2022-03-25
Primary completion: 2025-02-03
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.